Literature DB >> 9456673

Management of oral Kaposi's sarcoma and a proposal for clinical staging.

J B Epstein1.   

Abstract

Kaposi's sarcoma (KS) is the most common neoplastic disease in patients with disease due to human immunodeficiency virus (HIV), and oral KS (OKS) is the commonest oral neoplasia. OKS has been managed by local excision, intralesional chemotherapy regional radiotherapy, and systemic chemotherapy. Comparison between studies is difficult as the severity of oral involvement is not well defined in most studies. This paper reviews the approach to the management of OKS and also presents a proposal for the clinical staging of OKS. Clinical staging of OKS will facilitate comparisons of outcomes of treatment of OKS and improve our understanding of the natural history of the neoplasia, which has varied presentation and rates of progression.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9456673     DOI: 10.1111/j.1601-0825.1997.tb00342.x

Source DB:  PubMed          Journal:  Oral Dis        ISSN: 1354-523X            Impact factor:   3.511


  2 in total

Review 1.  Oral manifestations in HIV infection: fungal and bacterial infections, Kaposi's sarcoma.

Authors:  Peter A Reichart
Journal:  Med Microbiol Immunol       Date:  2003-03-05       Impact factor: 3.402

Review 2.  Emerging and re-emerging infectious disease in otorhinolaryngology.

Authors:  F Scasso; G Ferrari; G C DE Vincentiis; A Arosio; S Bottero; M Carretti; A Ciardo; S Cocuzza; A Colombo; B Conti; A Cordone; M DE Ciccio; E Delehaye; L Della Vecchia; I DE Macina; C Dentone; P DI Mauro; R Dorati; R Fazio; A Ferrari; G Ferrea; S Giannantonio; I Genta; M Giuliani; D Lucidi; L Maiolino; G Marini; P Marsella; D Meucci; T Modena; B Montemurri; A Odone; S Palma; M L Panatta; M Piemonte; P Pisani; S Pisani; L Prioglio; A Scorpecci; L Scotto DI Santillo; A Serra; C Signorelli; E Sitzia; M L Tropiano; M Trozzi; F M Tucci; L Vezzosi; B Viaggi
Journal:  Acta Otorhinolaryngol Ital       Date:  2018-04       Impact factor: 2.124

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.